Get the Stockscreener App
21.09
3.12%
-0.68
After Hours:
20.97
-0.12
-0.57%
Pacira Biosciences Inc stock is traded at $21.09, with a volume of 932.31K.
It is down -3.12% in the last 24 hours and down -11.76% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$21.77
Open:
$21.77
24h Volume:
932.31K
Relative Volume:
1.37
Market Cap:
$976.27M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
14.54
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-3.35%
1M Performance:
-11.76%
6M Performance:
-19.90%
1Y Performance:
+2.13%
1-Day Range:
$20.85
$21.86
1-Week Range:
$20.85
$22.74
52-Week Range:
$11.16
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.09 | 1.01B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
How does Pacira BioSciences Inc. generate profit in a changing economyPost Market Picks With Low Risk - jammulinksnews.com
Visualizing Pacira BioSciences Inc. stock with heatmapsTrade Alert System with Volume Analysis - Newser
New Product Launches: Will They Boost Pacira BioSciences Inc. Stock in 2025Daily Breakout List with Smart Filters - Newser
What the charts say about Pacira BioSciences Inc. todayMarket Forecast Summary Over Multi-Year Period - Newser
How to track smart money flows in Pacira BioSciences Inc.Price Action Based Buy Zone Forecast - Newser
Pacira BioSciences: A Strategic Transition with a Strong Balance Sheet and Long-Term Growth Catalysts - AInvest
Pacira BioSciences: Worth Pondering, Strong Balance Sheet (NASDAQ:PCRX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out - ACCESS Newswire
How did PCRX's Q4 earnings surprise investors? - AInvest
What makes Pacira BioSciences Inc. stock price move sharplyLong Term Equity Screener with Safety Metrics - Newser
Momentum Screeners Rank Pacira BioSciences Inc. in Top 5 TodayPrice Action Based Buy Opportunity List Published - metal.it
What are the technical indicators suggesting about Pacira BioSciences Inc.Advanced Screener Recommendation For 2025 - jammulinksnews.com
What catalysts could drive Pacira BioSciences Inc. stock higher in 2025Build wealth with long-term growth strategies - jammulinksnews.com
How volatile is Pacira BioSciences Inc. stock compared to the marketAccess exclusive market insights for free - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Connect - ACCESS Newswire
How many analysts rate Pacira BioSciences Inc. as a “Buy”Discover investment plans that deliver results - jammulinksnews.com
How does Pacira BioSciences Inc. compare to its industry peersGet daily updates on market movers and shakers - jammulinksnews.com
What is the dividend policy of Pacira BioSciences Inc. stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
What are Pacira BioSciences Inc. company’s key revenue driversGet daily updates on market movers and shakers - jammulinksnews.com
Is Pacira BioSciences Inc. Stock a Good Fit for Conservative InvestorsFree Investment Community - Newser
Intrinsic Value of Pacira BioSciences Inc. Stock: Is It Undervalued or OvervaluedBest Stocks for Capital Safety - Newser
Pacira BioSciences (NASDAQ:PCRX) Raised to “Buy” at Truist Financial - Defense World
What drives Pacira BioSciences Inc. stock priceHigh-profit trading signals - Autocar Professional
Is Pacira BioSciences Inc. stock overhyped or has real potentialConsistent double returns - jammulinksnews.com
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 - GlobeNewswire
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Pacira BioSciences Inc. stock performs during market volatilityFree Access to Community - Newser
Leading Non-Opioid Pain Therapy Maker Pacira Sets Q2 2025 Earnings DateKey Details Inside - Stock Titan
Pacira BioSciences, Inc. (NASDAQ:PCRX) Holdings Boosted by New York State Common Retirement Fund - Defense World
Is Pacira BioSciences Inc. a good long term investmentUnrivaled growth potential - jammulinksnews.com
Pacira BioSciences Partners with Johnson & Johnson to Enhance Zilretta Sales and Unlock Potential Upside - AInvest
What analysts say about Pacira BioSciences Inc. stockBreakthrough profit margins - jammulinksnews.com
Pacira BioSciences Inc. Stock Analysis and ForecastMarket-crushing stock picks - jammulinksnews.com
Pacira, JNJ in pact to boost Zilretta availability (PCRX) - Seeking Alpha
Pacira BioSciences Announces Strategic Collaboration to Signific - GuruFocus
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts - The Manila Times
Major Expansion: J&J to Co-Promote Pacira's ZILRETTA Across 7M Annual Knee Injections Market - Stock Titan
Bank of New York Mellon Corp Decreases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Has Negative Estimate for PCRX Q4 Earnings - Defense World
Teacher Retirement System of Texas Lowers Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):